Xspray Pharma Reports Positive P-I Trial Results of HyNap-Dasa for the Treatment of Chronic Myeloid Leukemia (CML)

 Xspray Pharma Reports Positive P-I Trial Results of HyNap-Dasa for the Treatment of Chronic Myeloid Leukemia (CML)

Xspray Pharma Reports Positive P-I Trial Results of HyNap-Dasa for the Treatment of Chronic Myeloid Leukemia (CML)

Shots:

  • The P-I BE study involves assessing of PK limitations i.e. Cmax, AUC for Xspray’s leading product HyNap-Dasa formulated vs Sprycel (Dasatinib)
  • The P-I study (N=16) with healthy candidates administrating single dose of each product, demonstrated positive results while confirming the validity of Xspray’s patented formulation technology
  • The results will be helpful in designing of planned registration study for ANDA application of HyNap-Dasa

Click here to read full press release/ article | Ref: PRNewswire | Image: Xspray Pharma

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post